文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

宫颈癌体外α/β比值变异及其对HDR近距离放疗EQD2的影响

In Vitro α/β Ratio Variations in Cervical Cancer, with Consequent Effects on Equivalent Dose in 2 Gy Fraction in High-Dose-Rate Brachytherapy.
PubMed 文献 · Adv Radiat Oncol · 2025-01-23

该研究分析了31篇文献中23种宫颈癌细胞系的98个体外α/β值,拟合概率分布并应用于三种外照射联合HDR近距离放疗处方,发现α/β值呈右偏对数正态分布,最可能值约4.3 Gy,其变异可导致EQD2不确定性达-8.0至46.4 Gy。

要点

  • 宫颈癌体外α/β值范围1.06–34.3 Gy,总体最可能值为4.25 Gy。
  • α/β变异导致EQD2不确定性为-8.0至46.4 Gy。
  • 83.9 Gy EQD2处方中,最可能α/β值所致偏差可达10 Gy。

核心结论

  • 宫颈癌体外α/β值变异大,呈右偏对数正态分布,最可能值约4.3 Gy。
  • 腺癌平均α/β值略低于鳞癌,但差异不足以得出明确结论。
  • 较低α/β值导致HDR近距离放疗EQD2高于α/β=10 Gy时的EQD2。

研究设计与样本

  • 分析31篇文献中23种宫颈癌细胞系的98个已发表体外α/β值。
  • 按鳞癌和腺癌组织学亚型分组,使用bootstrapped Kolmogorov-Smirnov拟合优度检验拟合概率分布。
  • 将概率分布应用于三种代表性外照射联合HDR近距离放疗处方以评估EQD2影响。

主要发现

  • 已发表α/β值范围为1.06至34.3 Gy。
  • 总体、鳞癌和腺癌的平均α/β值分别为8.05、8.47和6.60 Gy。
  • 总体、鳞癌和腺癌的最可能α/β值分别为4.25、4.34和4.22 Gy。
  • α/β值变异导致EQD2不确定性为-8.0至46.4 Gy。
  • 83.9 Gy EQD2处方中,平均α/β值导致EQD2偏差达4.3 Gy,最可能值导致偏差达10 Gy;该处方EQD2平均变异达预期剂量的8%。

关键数值与推荐

  • 总体平均α/β值为8.05 Gy,最可能值为4.25 Gy。
  • 鳞癌平均α/β值为8.47 Gy,最可能值为4.34 Gy。
  • 腺癌平均α/β值为6.60 Gy,最可能值为4.22 Gy。
  • 83.9 Gy EQD2处方中,最可能α/β值所致EQD2偏差可达10 Gy。

临床怎么用

  • 原文指出,较低α/β值相比α/β=10 Gy导致HDR近距离放疗更高的EQD2。
  • 原文建议,宫颈癌应使用更准确且可能更低的α/β值。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the distributions of published α/β values measured in vitro and the resulting uncertainties in the equivalent dose in 2 Gy fractions (EQD2) when applied to high-dose-rate brachytherapy (HDR-BT) for cervical cancer. METHODS AND MATERIALS: An analysis of 98 published α/β values from 31 papers was conducted, spanning 23 cervical cancer cell lines. Values were further divided into squamous cell carcinoma and adenocarcinoma histologies. Probability distributions were fit to histograms using the bootstrapped Kolmogorov-Smirnov goodness-of-fit test. Both average and most probable α/β values for cervical cancer were determined. The probability distributions were then applied to three representative external beam therapy (EBT) plus HDR brachytherapy prescriptions to determine the potential impact they would have on the equivalent dose in 2 Gy fractions (EQD2) for each prescription. RESULTS: Published results of α/β values ranged from 1.06 to 34.3 Gy. A right-skewed log-normal distribution was shown to be the best fit for overall α/β values as well as for squamous cell carcinoma and adenocarcinoma subtypes.. Average α/β values were determined to be 8.05, 8.47, and 6.60 Gy for the total, squamous cell carcinoma, and adenocarcinoma groups, respectively. The most probable values were 4.25, 4.34, and 4.22 Gy, respectively. The variations in α/β values led to uncertainties of -8.0 to 46.4 Gy in EQD2. Average α/β values resulted in EQD2 deviations of up to 4.3 Gy for the 83.9 Gy EQD2 prescription, whereas most probable values resulted in disparities as significant as 10 Gy. We used our α/β value distributions to create uncertainty distributions for EQD2 and discovered that the 83.9 Gy prescription in EQD2 had average variations of up to 8% from the intended dose. CONCLUSION: There was large variation in in vitro α/β values which presented as a right-skewed log-normal distribution with a most probable value of ∼4.3 Gy for cervical cancer. Adenocarcinoma showed somewhat lower average α/β values compared with squamous cell carcinoma, but the difference was not substantial enough to draw definitive conclusions. Lower α/β values resulted in higher EQD2 for HDR-BT compared with α/β values at 10 Gy. This suggests that more accurate and potentially lower α/β values should be used for cervical cancer.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Thayer-Freeman C, Washington B, Fabian D, et al. In Vitro α/β Ratio Variations in Cervical Cancer, with Consequent Effects on Equivalent Dose in 2 Gy Fraction in High-Dose-Rate Brachytherapy. Adv Radiat Oncol. 2025. PMID: 40062322. doi:10.1016/j.adro.2025.101725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。